1
|
Calderillo-Ruiz G, Lopez H, Padilla A, Diaz C, Miranda G, Lopez A, Carbajal B, Herrera A, Meneses A. Surgery specialization as a prognostic factor in colon cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Diaz C, Calderillo-Ruiz G, Ramos-Ramirez M, Herrera M, Manuel F, Horacio L, Ruiz-Garcia E, Itzel V, Ruan J, Miranda G, Gomez A, Meneses A. Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.342] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Nam M, Meneses A, Anstey C, Askew C, Hickman I, Bailey T, Quah J, Senior R, Cox S, Poulter R, Butterly S, Fryer M, Russell A, Stanton T, Greaves K. An Experimental Series Investigating the Effects of Euglycaemic Hyperinsulinaemia on Myocardial Blood Flow Reserve in Healthy Individuals and Perfusion Defect Size in Patients Presenting With Acute Myocardial Infarction. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Villareal-Garza CM, Platas A, Castro-Sánchez A, Miaja M, Bargalló-Rocha E, Martinez-Cannon BA, Vega Y, Fonseca A, Ramos-Elias P, Márquez-Perez CJ, Bukowski A, Goss P, St. Louis J, Chapman JA, Partridge A, Meneses A, Mohar A. Abstract P4-20-04: Young women with breast cancer in Mexico: A report of the pilot phase of the “Mujer Joven y Fuerte” prospective cohort. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-20-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite high rates of breast cancer in young women from low-and-middle-income countries (LMICs), their needs and concerns are not systematically studied or addressed. Understanding the characteristics of young women with breast cancer (YWBC) and the issues they face is of great relevance to the medical community, in order to tailor clinical interventions and supportive care for this unique and understudied patient population. The Mexican cohort “Mujer Joven y Fuerte” (Young and Strong Woman) has the goal of comprehensively characterizing and assessing the needs of YWBC in Mexico using patient- and physician-based surveys. Methods: A prospective cohort of newly diagnosed YWBC was established in November 2014 at two Mexican cancer centers in Mexico City and Monterrey. Eligible women answer web-based surveys on relevant topics including physical activity, genetics, psychosocial needs, and fertility. Clinicians complete pre-specified surveys using the US NIH BOLD Task Force common data elements registering clinical/pathologic characteristics and outcomes. Patients are evaluated at diagnosis, after 6 months, and annually for 5 years. Sub-studies assessing changes in cognition, sexual function and satisfaction, quality of life and depression/anxiety are being conducted, and biologic samples are stored for future research. Results: 96 YWBC with median age at diagnosis of 34 (21-41 y) were accrued to our pilot phase. 26% were single and 25% childless. 43% had higher education and 28% were employed. 90% presented with a self-detected mass. Clinical stage at diagnosis was distributed as follows: stage 0: 2%; I: 15%; IIA: 13%; IIB: 17%; III: 47%, and stage IV: 6%. The most frequent molecular subtype was HR+/HER2- (47%), followed by HER2+ (26%) and triple negative (21%). First follow-up results will be available shortly. Conclusions: To our knowledge, this represents the first prospective cohort of YWBC in Latin America. We are expanding this project to other centers in the region. Our findings will help develop culturally tailored interventions aimed at improving the psychosocial and medical outcomes of this vulnerable patient population.
Citation Format: Villareal-Garza CM, Platas A, Castro-Sánchez A, Miaja M, Bargalló-Rocha E, Martinez-Cannon BA, Vega Y, Fonseca A, Ramos-Elias P, Márquez-Perez CJ, Bukowski A, Goss P, St. Louis J, Chapman J-A, Partridge A, Meneses A, Mohar A. Young women with breast cancer in Mexico: A report of the pilot phase of the “Mujer Joven y Fuerte” prospective cohort [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-20-04.
Collapse
Affiliation(s)
- CM Villareal-Garza
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - A Platas
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - A Castro-Sánchez
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - M Miaja
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - E Bargalló-Rocha
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - BA Martinez-Cannon
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - Y Vega
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - A Fonseca
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - P Ramos-Elias
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - CJ Márquez-Perez
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - A Bukowski
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - P Goss
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - J St. Louis
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - J-A Chapman
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - A Partridge
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - A Meneses
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| | - A Mohar
- Instituto Nacional de Cancerologia, Mexico City, CDMX, Mexico; Program for Young Women with Breast Cancer, Mexico City, CDMX, Mexico; Breast Cancer Center, Tecnologico de Monterrey, Nuevo León, Monterrey, Mexico; MILC , Medicos e Investigadores en la Lucha Contra el Cáncer de Mama, Nuevo León, Monterrey, Mexico; MGH-Avon Breast Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA; (Retired) Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
5
|
Nam M, Meneses A, Richman T, Woo E, Karlsen E, McCracken A, Askew C, Anstey C, Byrne C, Stanton T, Russell A, Greaves K. The Dose-Response Effect of Hyperinsulinaemic Euglycaemia Using Insulin-Dextrose Clamps on Myocardial Microvascular Function. Heart Lung Circ 2017. [DOI: 10.1016/j.hlc.2017.06.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Nam M, Stanton T, Russell A, Hickman I, Askew C, Meneses A, Bailey T, Senior R, Byrne C, Karlsen E, Woo E, Greaves K. The Effect of Hyperinsulinaemic Euglycaemia on Myocardial Blood Flow Reserve in Healthy Volunteers Over Time. Heart Lung Circ 2016. [DOI: 10.1016/j.hlc.2016.06.651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Diaz C, Calderillo G, Marytere H, Ruiz-Garcia E, Manuel F, Trejo E, Horacio L, J Luis A, Herrera A, Meneses A, Alejandro P. P-132 The impact of obesity on complete pathologic response to neoadjuvant chemoradiotherapy in rectal cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Meneses A, Perez-Garcia G, Liy-Salmeron G, Ponce-López T, Lacivita E, Leopoldo M. 5-HT7 receptor activation: procognitive and antiamnesic effects. Psychopharmacology (Berl) 2015; 232:595-603. [PMID: 25074446 DOI: 10.1007/s00213-014-3693-0] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2014] [Accepted: 07/16/2014] [Indexed: 12/31/2022]
Abstract
RATIONALE The serotonin (5-hydroxytryptamine (5-HT)) 5-HT7 receptor is localized in brain areas mediating memory; however, the role of this receptor on memory remains little explored. OBJECTIVE First, demonstrating the associative nature of Pavlovian/instrumental autoshaping (P/I-A) task, rats were exposed (three sessions) to CS-US (Pavlovian autoshaping), truly random control, free operant, and presentations of US or CS, and they were compared with rats trained-tested for one session to the P/I-A procedure. Also, effects of the 5-HT7 receptor agonist LP-211 administered intraperitoneally after training was determined on short- (1.5 h) and long-term memory 24 and 48 h) and on scopolamine-induced memory impairment and cAMP production. METHODS Autoshaping and its behavioral controls were studied. Other animals were subjected to an autoshaping training session and immediately afterwards were given (intraperitoneal) vehicle or LP-211 (0.1-10 mg/kg) and/or scopolamine (0.2 mg/kg) and tested for short-term memory (STM) and long-term memory (LTM); their brains were extracted for the cAMP ELISA immunoassay. RESULTS P/I-A group produced the higher %CR. LP-211 did not affect STM; nonetheless, at 0.5 and 1.0 mg/kg, it improved LTM. The 5-HT7 receptor antagonist SB-269970 (SB; 10.0 mg/kg) alone had no effect; nevertheless, the LP-211 (1.0 mg/kg) LTM facilitation was reversed by SB. The scopolamine (0.2 mg/kg) induced-decrement in CR was accompanied by significant increased cAMP production. The scopolamine-induced decrement in CR and increments in cAMP were significantly attenuated by LP-211. CONCLUSIONS Autoshaping is a reliable associative learning task whose consolidation is facilitated by the 5-HT7 receptor agonist LP-211.
Collapse
Affiliation(s)
- A Meneses
- Depto. de Farmacobiología, CINVESTAV-IPN, México City, México,
| | | | | | | | | | | |
Collapse
|
9
|
Durá MJ, Merino F, Abajas R, Meneses A, Quesada A, González AM. High fidelity simulation in Spain: from dreams to reality. Rev Esp Anestesiol Reanim 2015; 62:18-28. [PMID: 24952828 DOI: 10.1016/j.redar.2014.05.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Revised: 05/06/2014] [Accepted: 05/07/2014] [Indexed: 06/03/2023]
Abstract
UNLABELLED Clinical simulation has emerged as a powerful new tool for the learning and assessment of different skills and attitudes in patient care, by using innovative technology such as high fidelity simulators (HFS). OBJECTIVE To describe the current state of high fidelity clinical simulation in Spain and its principal characteristics. METHODS Descriptive observational study that analyzes information on the clinical centers that have HFS in our country. RESULTS There are currently a total of 80 centers with HFS in our country, mainly distributed in university centers (43), hospital and emergency centers (27), simulation centers and institutes of simulation (5), and the rest (5) associated to entities of diverse ownership. The temporal development of HFS has been slowly progressive, with a significant growth in the last 6 years. The majority (74%) have specific facilities, auxiliary equipment (60%), and professionals with a shared commitment (80%). It is already integrated into the training programs in 56% of university centers with HFS. CONCLUSIONS The development of HFS has been remarkable in our country, and is mainly related to university undergraduate and postgraduate clinical medical education. It would be useful to design a network of simulation training centers of Health Sciences in Spain, which would be operational, sustainable and recognized, to optimize the use of these facilities.
Collapse
Affiliation(s)
- M J Durá
- Escuela de Enfermería, Universidad de Cantabria, Santander, España
| | - F Merino
- Escuela de Enfermería, Universidad de Cantabria, Santander, España
| | - R Abajas
- Escuela de Enfermería, Universidad de Cantabria, Santander, España
| | - A Meneses
- Escuela de Enfermería, Universidad Complutense de Madrid, Madrid, España
| | - A Quesada
- Unidad de Docencia Médica, Hospital Universitario Marqués de Valdecilla, Santander, España
| | - A M González
- Servicio de Anestesiología y Reanimación, Hospital Universitario Marqués de Valdecilla, Santander, España.
| |
Collapse
|
10
|
Villarreal-Garza CM, Hoyos CM, Meza-Herrera V, Palacios VA, Hernandez-Vega MB, Aguila C, Lara-Medina F, Meneses A, Mohar A. Abstract P5-12-10: Pathological characteristics and patterns of recurrence and mortality among young Mexican breast cancer patients. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-12-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In Mexico, it is recognized that breast cancer (BC) is diagnosed at younger ages than that reported in the US and other populations. Although national data is not available regarding BC age of diagnosis distribution, data from the INCAN, the main referral center in Mexico, showed that 17% of the total 893 newly diagnosed BC patients seen in 2012 were younger than 40 years old (which is more than twice that -7%- reported for US BC patients). We conducted a retrospective study in order to describe the frequency of BC among young Mexican BC patients, as well as their pathological characteristics at diagnosis and patters of recurrence.
Methods: Clinical and pathologic data from young pts (≤42 years old) who were newly diagnosed with invasive BC between January 2007 and December 2010 at the INCAN in Mexico and were followed for at least 2 years were identified. Clinical stage at diagnosis was recorded and estrogen receptor, progesterone receptor and HER2 expression were determined by immunohistochemistry and/or FISH. Proportion differences were tested using the Chi-square test.
Results: 445 young patients were identified from a total of 2919 BC patients (15%). A total of 320 patients met the inclusion criteria for analysis. Median age of diagnosis was 36 years (19-42). 49% of patients were very young patients (≤ 35 years). 19% were diagnosed as early disease, 67.5% as locally advanced BC and 13.5% as metastatic. 32% of patients had triple negative BC disease, while 27% were HER2 positive. From the non-metastatic patients at diagnosis, 31% developed recurrence (65% systemic, 21% loco regional and 14% both). After a median follow-up of 26 months, 18% of the 320 patients died secondary to BC disease progression.
Conclusions: Although this series corresponds to patients treated at a reference national center, the data reported in this study suggests that BC among young women is very prevalent in Mexico compared to other populations. The causes underlying the striking difference in age at diagnosis in Mexican BC patients are unknown and have not been investigated, including the genetic contributing factors. As reported in non-Hispanic population studies, BC among young women is diagnosed in more advanced stages, and triple-negative and HER2 positive diseases are more frequent. It is associated with a high proportion of systemic and loco regional recurrence, with a dismal prognosis. Due to the substantial number of BC cases among young women in Mexico, its prospective study is more than justified. In order to meet with this goal, our group is preparing the establishment of the Mexican Young Women's Breast Cancer Cohort Program at the INCAN in Mexico and to launch the related scientific projects related to this plan.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-12-10.
Collapse
Affiliation(s)
- CM Villarreal-Garza
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| | - CM Hoyos
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| | - V Meza-Herrera
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| | - VA Palacios
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| | - MB Hernandez-Vega
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| | - C Aguila
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| | - F Lara-Medina
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| | - A Meneses
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| | - A Mohar
- Instituto Nacional de Cancerología, Mexico, DF; Universidad Particular San Martin de Porres, Lima
| |
Collapse
|
11
|
Noren G, Chabat P, Meneses A, Linder C, González J. Translocation of an Intrauterine Contraceptive Device: Incidental Finding in the Vesicouterine Fold. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Meneses A, Ponce-Lopez T, Tellez R, Gonzalez R, Castillo C, Gasbarri A. Effects of d-amphetamine on short- and long-term memory in spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley rats. Behav Brain Res 2010; 216:472-6. [PMID: 20813138 DOI: 10.1016/j.bbr.2010.08.035] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Revised: 08/15/2010] [Accepted: 08/20/2010] [Indexed: 12/15/2022]
Abstract
Diverse studies indicate that the attention deficit hyperactivity disorder (ADHD) is associated with alterations in encoding processes, including working or short-term memory. Some ADHD dysfunctional domains are reflected in the spontaneously hypertensive rat (SHR). Here SHR-saline group showed significantly poor STM and LTM relative to SD and WKY saline rats. SD and WKY rats treated with d-amphetamine displayed better STM and LTM, compared to SD-vehicle, WKY-vehicle or SHR-d-amphetamine groups.
Collapse
Affiliation(s)
- A Meneses
- Department of Pharmacobiology, CINVESTAV, Mexico City, Mexico.
| | | | | | | | | | | |
Collapse
|
13
|
Meneses A, Epaulard O, Maurin M, Gressin R, Pavese P, Brion JP, Garin-Bastuji B, Stahl JP. Réactivation bactériémique d’une brucellose 70ans après la primo-infection. Med Mal Infect 2010; 40:238-40. [DOI: 10.1016/j.medmal.2009.08.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2009] [Revised: 04/19/2009] [Accepted: 08/28/2009] [Indexed: 11/27/2022]
|
14
|
Huerta-Rivas A, Pérez-García G, González-Espinosa C, Meneses A. Time-course of 5-HT6 receptor mRNA expression during memory consolidation and amnesia. Neurobiol Learn Mem 2010; 93:99-110. [DOI: 10.1016/j.nlm.2009.08.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2009] [Revised: 08/24/2009] [Accepted: 08/28/2009] [Indexed: 11/28/2022]
|
15
|
Mayoral MA, Mayoral C, Meneses A, Villalvazo L, Guzmán A, Espinosa B, Ochoa JL, Zenteno E, Guevara J. Identification of Galectin-3 and Mucin-Type O-Glycans in Breast Cancer and Its Metastasis to Brain. Cancer Invest 2009; 26:615-23. [DOI: 10.1080/07357900701837051] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
16
|
Garcia-Hernandez N, Arenas D, Murillo-Ortiz B, Meneses A, Muñoz D, Ruiz-Garcia E, Astudillo-de la Vega H. Biomarker analysis by tissue microarray technology of Bik, Bcl-2, Bax, ER-α, ER-β, Her2/neu, PCNA, P53, pRB proteins and apoptotic index (by TUNEL) in breast cancer Mexican biopsies. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-4043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #4043
Background: 
 The development and progression of epithelial cancers are the results of changes in many genetic networks. Through massive analysis techniques various prognostic factors have been studied to determine proteins implicated in cancer. A new technology used is tissue microarray (TMAs), which allows the assessment of several patients at different stages in a single slide.
 Methods:
 TMA blocks with up to 128 cylinders were made by using 1.5-mm diameter tissue cores from each paraffin block. In a series of 70 formalin-fixed carcinomas, we analyzed the immuno-expression of Bik, Bcl-2, Bax, ER-α, ER-β, Her2, PCNA, P53 and RB proteins. For apoptosis detection the TUNEL technique was used. Expression profiles for these tumors were generated with an unsupervised clustering and a T Test analysis.
 Results:
 We developed TMAs with samples from Mexican women with breast cancer at different stages (type I, II and III) and compared these with those of non affected breast tissue of the same women's samples. Through a hierarchical cluster we found three subgroups of tumors according to protein expression behavior. The apoptotic process was found in low grade 4.28%; moderate grade 90% and high grade 5.71% of samples. Statistical analysis revealed that Bax gene (p=0.000) expression was significantly increased in samples stage I and underexpressed in samples stage IIIA. The Bcl-2 gene was under-expressed in the majority of samples of the stage II. Even when the Bik gene was detected the protein level was over-expressed in 44.29% of the cases with noa significant correlation with apoptosis (TUNEL) (p=0.006). The samples where there were more alterations of the studied proteins were understood in the stages IIA (T2N0M0) and IIB (T2N1M0).
 
 Conclusions:
 The analysis of specimens of several patients in different stages of the disease turns out to be useful to establish a better diagnosis and prognosis. Differential regulation of these genes, especially Bik and Bax, may contribute to the biological nature of a clinically more aggressive and highly proliferative breast cancers.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4043.
Collapse
Affiliation(s)
- N Garcia-Hernandez
- 1 Laboratorio de Genetica Humana UIMGH, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
| | - D Arenas
- 1 Laboratorio de Genetica Humana UIMGH, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
| | - B Murillo-Ortiz
- 2 Unidad de Investigación Clinica UMAE No. 1 Bajio, Instituto Mexicano del Seguro Social, Leon, Guanajuato, Mexico
| | - A Meneses
- 3 Departamento de Patologia, Instituto Nacional de Cancerologia, Mexico, DF, Mexico
| | - D Muñoz
- 4 Departamento de Ginecologia, Instituto Nacional de Cancerologia, Mexico, DF, Mexico
| | - E Ruiz-Garcia
- 5 Laboratorio de Oncologia Molecular UIMEO, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
| | - H Astudillo-de la Vega
- 5 Laboratorio de Oncologia Molecular UIMEO, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
| |
Collapse
|
17
|
Perez-Garcia G, Meneses A. Memory formation, amnesia, improved memory and reversed amnesia: 5-HT role. Behav Brain Res 2008; 195:17-29. [DOI: 10.1016/j.bbr.2007.11.027] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2007] [Revised: 11/27/2007] [Accepted: 11/27/2007] [Indexed: 11/16/2022]
|
18
|
Meneses A, Perez-Garcia G, Liy-Salmeron G, Flores-Galvez D, Castillo C, Castillo E. The effects of the 5-HT6 receptor agonist EMD and the 5-HT7 receptor agonist AS19 on memory formation. Behav Brain Res 2008; 195:112-9. [DOI: 10.1016/j.bbr.2007.11.023] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2007] [Accepted: 11/22/2007] [Indexed: 10/22/2022]
|
19
|
Perez-García G, Meneses A. Ex vivo study of 5-HT(1A) and 5-HT(7) receptor agonists and antagonists on cAMP accumulation during memory formation and amnesia. Behav Brain Res 2008; 195:139-46. [PMID: 18723050 DOI: 10.1016/j.bbr.2008.07.033] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2008] [Revised: 07/14/2008] [Accepted: 07/15/2008] [Indexed: 11/30/2022]
Abstract
The cyclic adenosine monophosphate (cAMP) is a second messenger and a central component of intracellular signaling pathways that regulate a wide range of biological functions, including memory. Hence, in this work, firstly the time-course of memory formation was determined in an autoshaping learning task, which had allowed the identification of testing times for increases or decreases in performance. Next, untrained, trained and overtrained groups were compared in cAMP production. Moreover, selective stimulation and antagonism of 5-HT(1A) and 5-HT(7) receptors during memory formation and cAMP production were determined. Finally, since there is scarce information about how pharmacological models of amnesia affect cAMP production, the cholinergic or glutamatergic antagonists, scopolamine and dizocilpine, were tested. The major findings of this work showed that when the time-course was determined inasmuch as training and testing sessions occurred, memory performance was graduate and progressive. Notably, for the fourth to seventh (i.e., 48-120 h following autoshaping training session) testing session performance was significantly higher from the previous ones. When animals received 5-HT(1A) and 5-HT(7) receptor agonists and antagonists or amnesic drugs significant increases or decrements in memory performance were observed at 24 and 48 h. Moreover, when ex vivo cAMP production from trained and overtrained groups were compared to untrained ones, significant differences were observed among groups and brain areas. Trained animals treated with 8-OHDPAT, AS19, 8-OHDPAT plus AS19, WAY100635, SB-269970, scopolamine or dizocilpine were compared to similar untrained groups, and eightfold-reduced cAMP production was evident, showing the importance of cAMP production in the signaling case in mammalian memory formation.
Collapse
Affiliation(s)
- G Perez-García
- Department of Pharmacobiology, CINVESTAV, Tenorios 235, Granjas Coapa, 14330 Mexico City, Mexico.
| | | |
Collapse
|
20
|
Santoro M, Meneses A. Haematology and plasma chemistry of breeding olive ridley sea turtles (Lepidochelys olivacea). Vet Rec 2007; 161:818-819. [PMID: 18083982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Affiliation(s)
- M Santoro
- Departamento de Patología, Escuela de Medicina Veterinaria, Universidad Nacional, PO Box 86 Heredia 3000, Costa Rica
| | | |
Collapse
|
21
|
Muñoz D, Cantu D, Gonzalez A, Meneses A, Mohar A, Astudillo-de la Vega H, Nguyen B. A phase II trial of the use of 4,4’-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone (A-007) topical gel in the treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5593] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5593 Background: The incidence of cervical cancer is highly correlated with cervical high grade squamous intraepithelial lesions (HSIL [CIN2/3]) and human papillomavirus (HPV) infection in men and women. Approximately 70 - 80% of sexually active adolescents and adults will become infected with HPV during their lifetime. In 2003 alone, there were 50 million cases of HPV infections in the United States. Our main objective is to determine the pathological response (complete and partial, based on independent review panel of two patho the uterine cervix of women with HSIL [CIN 2/3]. Materials and Methods: Following colposcopy, pap smear and biopsy confirmation of HSIL (CIN 2/3) and HPV infection status, women are treated with gel applied to the cervix via an intravaginal applicator once daily for 5 consecutive days of a 28-day cycle for 2 cycles. At month 4 post enrollment into the trial, all women undergo the loop electrosurgical excision procedure (LEEP) procedure and repeated virology assessment. Results: 65 patients were enrolled at 2 centers and completed treatment with A-007 and 100% (65/65) were HPV positive (81.5% by Hibrid Capture II for High Risk and 100% PCR positive). All baseline and LEEP pathological specimens will be blinded read by a panel of two independent expert pathologists. A subject will be considered a complete pathological responder (CR) when the patient has regression of HSIL (CIN 2/3) without pathological evidence of HSIL, and a partial pathological responder (PR) when she has regression of HSIL (CIN 2/3) to LSIL (CIN 1). Overall response rate is defined as the percentage of patients with CR and PR. To date, no serious adverse events (SAE) has been reported during treatment in all enrolled patients, only has been reported a moderate local and transitory itching/burning sensation during the first 5–20 minutes after application in 18% (12/65) of the cases. At this moment LEEP procedures are being scheduled for all patients and the pathological response rate as well as the HPV response rate will be available and presented at the conference. [Table: see text]
Collapse
Affiliation(s)
- D. Muñoz
- National Institute of Cancerology, Mexico City, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico; IMSS, Mexico City, Mexico; Tigris Pharmaceuticals, Inc., Bonita Springs, FL
| | - D. Cantu
- National Institute of Cancerology, Mexico City, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico; IMSS, Mexico City, Mexico; Tigris Pharmaceuticals, Inc., Bonita Springs, FL
| | - A. Gonzalez
- National Institute of Cancerology, Mexico City, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico; IMSS, Mexico City, Mexico; Tigris Pharmaceuticals, Inc., Bonita Springs, FL
| | - A. Meneses
- National Institute of Cancerology, Mexico City, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico; IMSS, Mexico City, Mexico; Tigris Pharmaceuticals, Inc., Bonita Springs, FL
| | - A. Mohar
- National Institute of Cancerology, Mexico City, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico; IMSS, Mexico City, Mexico; Tigris Pharmaceuticals, Inc., Bonita Springs, FL
| | - H. Astudillo-de la Vega
- National Institute of Cancerology, Mexico City, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico; IMSS, Mexico City, Mexico; Tigris Pharmaceuticals, Inc., Bonita Springs, FL
| | - B. Nguyen
- National Institute of Cancerology, Mexico City, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico; IMSS, Mexico City, Mexico; Tigris Pharmaceuticals, Inc., Bonita Springs, FL
| |
Collapse
|
22
|
Abstract
Evidence from invertebrates to human studies indicates that serotonin (5-hydroxytryptamine; 5-HT) system modulates short- (STM) and long-term memory (LTM). This work is primarily focused on analyzing the contribution of 5-HT, cholinergic and glutamatergic receptors as well as protein synthesis to STM and LTM of an autoshaping learning task. It was observed that the inhibition of hippocampal protein synthesis or new mRNA did not produce a significant effect on autoshaping STM performance but it did impair LTM. Both non-contingent protein inhibition and 5-HT depletion showed no effects. It was basically the non-selective 5-HT receptor antagonist cyproheptadine, which facilitated STM. However, the blockade of glutamatergic and cholinergic transmission impaired STM. In contrast, the selective 5-HT(1B) receptor antagonist SB-224289 facilitated both STM and LTM. Selective receptor antagonists for the 5-HT(1A) (WAY100635), 5-HT(1D) (GR127935), 5-HT(2A) (MDL100907), 5-HT(2C/2B) (SB-200646), 5-HT(3) (ondansetron) or 5-HT(4) (GR125487), 5-HT(6) (Ro 04-6790, SB-399885 and SB-35713) or 5-HT(7) (SB-269970) did not impact STM. Nevertheless, WAY100635, MDL100907, SB-200646, GR125487, Ro 04-6790, SB-399885 or SB-357134 facilitated LTM. Notably, some of these changes shown to be independent of food-intake. Concomitantly, these data indicate that '5-HT tone via 5-HT(1B) receptors' might function in a serial manner from STM to LTM, whereas working in parallel using 5-HT(1A), 5-HT(2A), 5-HT(2B/2C), 5-HT(4), or 5-HT(6) receptors.
Collapse
Affiliation(s)
- A Meneses
- Depto de Farmacobiología, CINVESTAV-IPN, Tenorios 235, Granjas Coapa, México City, Mexico.
| |
Collapse
|
23
|
Meneses A, Manuel-Apolinar L, Castillo C, Castillo E. Memory consolidation and amnesia modify 5-HT6 receptors expression in rat brain: An autoradiographic study. Behav Brain Res 2007; 178:53-61. [PMID: 17267053 DOI: 10.1016/j.bbr.2006.11.048] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2006] [Revised: 11/27/2006] [Accepted: 11/29/2006] [Indexed: 10/23/2022]
Abstract
Traditionally, the search for memory circuits has been centered on examinations of amnesic and AD patients, cerebral lesions and, neuroimaging. A complementary alternative might be the use of autoradiography with radioligands. Indeed, ex vivo autoradiographic studies offer the advantage to detect functionally active receptors altered by pharmacological tools and memory formation. Hence, herein the 5-HT(6) receptor antagonist SB-399885 and the amnesic drugs scopolamine or dizocilpine were used to manipulate memory consolidation and 5-HT(6) receptors expression was determined by using [(3)H]-SB-258585. Thus, memory consolidation was impaired in scopolamine and dizocilpine treated groups relative to control vehicle but improved it in SB-399885-treated animals. SB-399885 improved memory consolidation seems to be associated with decreased 5-HT(6) receptors expression in 15 out 17 brain areas. Scopolamine or dizocilpine decreased 5-HT(6) receptors expression in nine different brain areas and increased it in CA3 hippocampus or other eight areas, respectively. In brain areas thought to be in charge of procedural memory such basal ganglia (i.e., nucleus accumbens, caudate putamen, and fundus striate) data showed that relative to control animals amnesic groups showed diminished (scopolamine) or augmented (dizocilpine) 5-HT(6) receptor expression. SB-399885 showing improved memory displayed an intermediate expression in these same brain regions. A similar intermediate expression occurs with regard to amygdala, septum, and some cortical areas in charge of explicit memory storage. However, relative to control group amnesic and SB-399885 rats in the hippocampus, region where explicit memory is formed, showed a complex 5-HT(6) receptors expression. In conclusion, these results indicate neural circuits underlying the effects of 5-HT(6) receptor antagonists in autoshaping task and offer some general clues about cognitive processes in general.
Collapse
Affiliation(s)
- A Meneses
- Depto. de Farmacobiología, CINVESTAV-IPN, Tenorios 235, Granjas Coapa, Mexico City 14330, Mexico.
| | | | | | | |
Collapse
|
24
|
Ruíz-Godoy L, Suárez L, Mosqueda A, Meneses A. Polymorphous low-grade adenocarcinoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal 2007; 12:E30-3. [PMID: 17195824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023] Open
Abstract
Polymorphous low-grade adenocarcinoma (PLGA) is difficult to diagnose both clinically and histologically due to its indolent presentation, and because of its morphological diversity that includes several microscopic patterns. The aggressive biologic behavior seen in minor salivary glands as compared to major glands is apparently associated histologically to a predominance of the papillary pattern in the former. Biologic behavior of PLGA in the major salivary glands is uncertain, as some cases have developed recurrences and metastases independently of the presence of a papillary pattern. A case of PLGA originated de novo in parotid gland is presented a 60 year-old male, treatment was surgically excised through superficial parotidectomy and to postoperative radiotherapy (46 Gy). Forty-eight months later the patient is alive with no signs of recurrence, as well as a review of the literature, with particular emphasis in its differential diagnosis and biological behavior.
Collapse
|
25
|
Ruíz-Godoy R LM, Garcia-Cuellar CM, Herrera González NE, Suchil BL, Pérez-Cárdenas E, Sácnchez-Pérez Y, Suárez-Roa ML, Meneses A. Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. J Exp Clin Cancer Res 2006; 25:73-8. [PMID: 16761621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
The ras gene family (H, K and N-ras) encodes the Ras protein, a GTPase-activating protein that regulates several signal transduction pathways including cellular proliferation and differentiation. Mutations in codons 12, 13 and 61 of the ras genes constitute one of the most frequent alterations in human cancer. In the Western Hemisphere, a low frequency of mutations in these genes has been observed in head and neck carcinomas; a higher frequency has been found in countries such as India and Taiwan. Increased protein expression is a relatively frequent event in larynx carcinomas. This study was aimed to evaluate the participation of the k-ras gene and Ras expression in 20 Mexican patients with larynx squamous carcinoma, 2 with dysplasia and 4 with normal mucosa. Samples (of 26 patients) were embedded in paraffin and immunohistochemical analysis was performed for the Ras protein, as well as amplification of the k-ras gene exon 1 (108 bp) by laser capture microdissection. Then, DNA extraction, PCR and sequencing were performed looking for possible mutation in codons 12 and 13. All patients with larynx carcinoma were men, median age 62 years. Eighty-five percent of the patients had risk factors such as smoking and/or alcohol consumption, 25% were in clinical stages I and II, and 75% in stages III and IV; 45% of the patients presented tumor recurrence or persistence. In this study, no mutations were found in codons 12 or 13 of the k-ras gene; however, protein expression was observed in 95% of the samples and a higher expression of the protein was associated with tumor recurrence or persistence, although this was not statistically significant. Unexpectedly, well-differentiated carcinomas and dysplasias presented an increase in protein expression. These results suggest that ras may be involved in early stages of larynx carcinogenesis and may be activated by other mechanisms different from mutations, such as epigenetic events.
Collapse
Affiliation(s)
- L M Ruíz-Godoy R
- Basic Research Subdirection, National Institute of Cancerology, Tlalpan, Mexico
| | | | | | | | | | | | | | | |
Collapse
|
26
|
García-López P, Coll M, Cervera E, Reyes-Vermot L, Torres MA, Abrego-Pérez G, Hernández-Pájaro AI, Castañeda-Hernandez G, Mohar-Betancourt A, Meneses A. The Systemic Absorption of Etoposide after Intravaginal Administration in Patients with Cervical Intraepithelial Lesions Associated with Human Papillomavirus Infection. Pharm Res 2006; 23:378-83. [PMID: 16388409 DOI: 10.1007/s11095-005-9142-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2005] [Accepted: 10/14/2005] [Indexed: 10/25/2022]
Abstract
PURPOSE The purpose of this study was to determine the systemic absorption and the release of etoposide in cervical tissue administered via a vaginal ovule to women diagnosed with cervical intraepithelial lesions associated with human papillomavirus (HPV). METHODS Fifteen women with low- and high-grade intraepithelial neoplasia confirmed by colposcopic test received a 50-mg intravaginal etoposide dose three times a week for 3 weeks. At the end of the study period, paralleled with the last ovule administered, blood samples were collected over a period of 24 h, and in situ cervical samples were obtained at 3 and 10 h after drug administration. Etoposide concentrations were determined in plasma and in in situ cervical samples using the high-performance liquid chromatography method with electrochemical detection. RESULTS Pharmacokinetic analyses of plasma data indicated low or lack of systemic exposure of etoposide after the vaginal administration. Nevertheless, high concentrations of etoposide were found in all in situ cervical samples, indicating that etoposide could be released from its pharmaceutical formulation. CONCLUSIONS The results of the study suggest that the etoposide administered as intravaginal ovule is safe and tolerable and apparently could be a suitable option in patients with cervical intraepithelial neoplasia. Clinical results and the true impact on HPV infection and evolution of dysplasia need to be confirmed.
Collapse
Affiliation(s)
- P García-López
- División de Investigación Básica, Instituto Nacional de Cancerología, INCan, Av. San Fernando # 22 Tlalpan, 14000 México, D.F., México.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Luna-Munguía H, Manuel-Apolinar L, Rocha L, Meneses A. 5-HT1A receptor expression during memory formation. Psychopharmacology (Berl) 2005; 181:309-18. [PMID: 15778876 DOI: 10.1007/s00213-005-2240-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2004] [Accepted: 02/08/2005] [Indexed: 10/25/2022]
Abstract
RATIONALE It has been reported that 5-HT(1A) receptors modulate learning and memory and diverse pharmacological and genetic evidence supports this notion. Nevertheless, there are few works about expression of these receptors during memory formation. OBJECTIVE We aimed to determine 5-HT(1A) receptor expression in brain areas of untrained, passive, and autoshaping trained groups of rats. METHODS Ex vivo receptor autoradiography using the ligand agonist [(3)H]8-hydroxy-2-[di-n-propylamino]tetralin] (8-OH-DPAT) was used. RESULTS The trained group relative to untrained animals showed increases of 5-HT(1A) receptor expression in 14 brain areas, decrements in 7, and no changes in 12. Thus, in contrast to untrained rats, 5-HT(1A) receptor expression of autoshaping trained rats was augmented in the tubercule olfactory, septal nucleus, nucleus accumbens, caudate putamen, globus pallidus, striate, and parietal (1 and 2), temporal cortex (1 and 3), granular retrosplenial cortex (1), amygdala, and median and dorsal raphe nuclei. In contrast, in the latter group, receptors were decreased in the CA1 area, hypothalamus dorsal, frontal cortex (1 and 3), occipital cortex, cingulate cortex (1 and 2), and cuneiform nucleus. There were significant differences between passive vs trained groups, but not regarding untrained rats, in the lateral olfactory tract, dentate gyrus, CA3 area, ventromedial hypothalamic, lateral hypothalamus, preoptic medial, frontal cortex (2), granular retrosplenial cortex (2), entorhinal cortex (1 and 2), piriform cortex, and substantia nigra. CONCLUSIONS These data suggest that upregulated, downregulated, and "silence" of 5-HT(1A) receptors in brain areas form part of neural circuits engaged in memory formation by demonstrating a high degree of specificity and memory mapping.
Collapse
Affiliation(s)
- H Luna-Munguía
- Departo. Farmacobiología, CINVESTAV-IPN, Tenorios 235, Granjas Coapa, México City
| | | | | | | |
Collapse
|
28
|
Perez-García GS, Meneses A. Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task. Behav Brain Res 2005; 163:136-40. [PMID: 15936093 DOI: 10.1016/j.bbr.2005.04.014] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2005] [Revised: 04/19/2005] [Accepted: 04/20/2005] [Indexed: 10/25/2022]
Abstract
This work aimed to evaluate further the role of 5-HT7 receptors during memory formation in an autoshaping Pavlovian/instrumental learning task. Post-training administration of the potential 5-HT7 receptor agonist AS 19 or antagonist SB-269970 enhanced memory formation or had no effect, respectively. The AS 19 facilitatory effect was reversed by SB-269970, but not by the selective 5-HT1A antagonist WAY100635. Amnesia induced by scopolamine (cholinergic antagonist) or dizocilpine (NMDA antagonist) was also reversed by AS 19. Certainly, reservations regarding the selectivity of AS 19 for 5-HT7 and other 5-HT receptors in vivo are noteworthy and, therefore, its validity for use in animal models as a pharmacological tool. Having mentioned that, it should be noticed that together these data are providing further support to the notion of the 5-HT7 receptors role in memory formation. Importantly, this 5-HT7 receptor agonist AS 19 appears to represent a step forward respect to the notion that potent and selective 5-HT7 receptor agonists can be useful in the treatment of dysfunctional memory in aged-related decline and Alzheimer's disease.
Collapse
Affiliation(s)
- Georgina S Perez-García
- Department of Pharmacobiology, CINVESTAV-IPN, Tenorios #235, Granjas Coapa, México City 14330, México
| | | |
Collapse
|
29
|
Manuel-Apolinar L, Rocha L, Pascoe D, Castillo E, Castillo C, Meneses A. Modifications of 5-HT4 receptor expression in rat brain during memory consolidation. Brain Res 2005; 1042:73-81. [PMID: 15823255 DOI: 10.1016/j.brainres.2005.02.020] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2004] [Revised: 02/01/2005] [Accepted: 02/07/2005] [Indexed: 11/24/2022]
Abstract
Pharmacological evidence indicates a specific role of 5-HT(4) receptors on memory function. These receptors are members of G-protein-coupled 7-transmembrane domain receptor superfamily, are positively coupled to adenylyl cyclase, and are heterogeneously located in some structures important for memory, such as the hippocampus and cortical regions. To further clarify 5-HT(4) receptors' role in memory, the expression of these receptors in passive (P3) untrained and autoshaping (A3) trained (3 sessions) adult (3 months) and old (P9 or A9; 9 months) male rats was determined by autoradiography. Adult trained (A3) rats showed a better memory respect to old trained (A9). Using [(3)H] GR113808 as ligand (0.2 nM specific activity 81 Ci/mmol) for 5-HT(4) receptor expression, 29 brain areas were analyzed, 16 areas of A3 and 17 of A9 animals displayed significant changes. The medial mammillary nucleus of A3 group showed diminished 5-HT(4) receptor expression, and in other 15 brain areas of A3 or 10 of A9 animals, 5-HT(4) receptors were increased. Thus, for A3 rats, 5-HT(4) receptors were augmented in olfactory lobule, caudate putamen, fundus striatum, CA2, retrosplenial, frontal, temporal, occipital, and cingulate cortex. Also, 5-HT(4) receptors were increased in olfactory tubercule, hippocampal CA1, parietal, piriform, and cingulate cortex of A9. However, hippocampal CA2 and CA3 areas, and frontal, parietal, and temporal cortex of A9 rats, expressed less 5-HT(4) receptors. These findings suggest that serotonergic activity, via 5-HT(4) receptors in hippocampal, striatum, and cortical areas, mediates memory function and provides further evidence for a complex and regionally specific regulation over 5-HT receptor expression during memory formation.
Collapse
|
30
|
Meneses A, Manuel-Apolinar L, Rocha L, Castillo E, Castillo C. Expression of the 5-HT receptors in rat brain during memory consolidation. Behav Brain Res 2004; 152:425-36. [PMID: 15196811 DOI: 10.1016/j.bbr.2003.10.037] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2003] [Revised: 10/18/2003] [Accepted: 10/21/2003] [Indexed: 11/17/2022]
Abstract
Serotonin (5-hydroxytryptamine, 5-HT) system displays more than 14 receptors subtypes on brain areas involved in learning and memory processes, and pharmacological manipulation of specific receptors selectively affects memory formation. In order to begin the search of 5-HT receptors expression during memory formation, in this work, we aimed to determine, by autoradiography (using 3H 5-HT as ligand, 2 nM, specific activity 123 Ci/mmol), 5-HT receptors (5-HTR) expression in passive (untrained) and autoshaping trained (3 sessions) adult (3 months) and old (9 months) male rats. Thus, trained adult rats had better retention than old animals. Raphe nuclei of adult and old trained rats expressed less receptors on medial and dorsal, respectively. Hippocampal CA1 area and dentate gyrus of adult trained rats expressed less 5-HTR, while dentate gyrus of old increased them. Basomedial amygdaloid nucleus in old trained rats expressed more 5-HTR; while in the basolateral amygdaloid nucleus they were augmented in both groups. Training decreased or did not change 5-HTR in caudate-putamen of adult or old animals. The above profile of 5-HTR expression is consistent with previous reports, and suggests that memory formation and aging modulates 5-HTR expression in brain areas relevant to memory systems.
Collapse
Affiliation(s)
- A Meneses
- Departamento de Farmacobiología, CINVESTAV-IPN, Tenorios 235, Granjas Coapa, Mexico City 14330, Mexico.
| | | | | | | | | |
Collapse
|
31
|
Abstract
Animals were submitted to an associative learning task named Pavlovian/instrumental autoshaping (P/I-A) and treated with selective 5-HT1A and 5-HT7 receptor agonists and antagonists. Next, they were sacrificed, their brains removed, dissected and changes on cortical and hippocampal cyclic adenosine monophosphate (cAMP) production were determined. Results revealed that, the 8-OH-DPAT treatment facilitated memory consolidation of autoshaping and that effect was blocked completely by WAY100635 and partially by DR4004. WAY100635 or DR4004 alone had no effect on autoshaping. The cAMP results were complex and yielded no clear relationship to the memory results. Thus, cortical and hippocampal increased on cAMP production was observed following administration of the 5-HT(1A/7) agonist 8-OH-DPAT. The memory effect was, completely or partially, reversed by the selective antagonists WAY100635 (5-HT1A) or DR4004 (5-HT7), respectively.
Collapse
Affiliation(s)
- L Manuel-Apolinar
- Escuela de Medicina, IPN, Tenorios 235, Granjas Coapa, México City 14330, Mexico
| | | |
Collapse
|
32
|
Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW, de la Garza J, Hadden E. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 2003; 3:1073-81. [PMID: 12860164 DOI: 10.1016/s1567-5769(03)00029-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
A Phase II trial in 42 patients with squamous cell cancer of the head and neck (H and NSCC) was performed using a combination immunotherapy with 10-20 days of perilymphatic injections of a natural cytokine mixture (NCM: IRX-2; 200 units IL-2 equivalence) preceded by low dose cyclophosphamide (CY; 300 mg/m(2)) and followed by daily oral indomethacin (25 mg t.i.d.) and zinc (65 mg in a multivitamin preparation). Thirty-nine patients underwent subsequent surgical resection and 22 stage IV patients received additional radiotherapy. Forty-two percent were adjudged to have complete and partial clinical responses (>50% tumor reduction); an additional five patients had minor responses for a total of 58%. Comparison of post-treatment biopsies or surgical specimens showed 90% of patients had reduction in tumor area from 79% to 48% (over half of which was fragmented) and increased area of leukocyte infiltration from 9% to 32% (79% of which was lymphoid). The treatment with IRX-2 was not associated with significant side effects and 24 of patients showed improvement in eating, breathing or phonation or reduced pain and bleeding. Fifteen patients with lymphocytopenia (lymphocyte counts [LC] less than or equal to 1500 mm(3)) showed significant increases in LC, CD3+, CD4+ and CD8+ T lymphocytes of 401, 147, 95 and 100/mm(3), respectively. Analysis of outcome of 32 on protocol patients after 36 months versus 32 concurrent institutional H and NSCC controls showed delayed recurrences and significant increases in mean survival time (MST) and survival (p's<0.02). The data document immunotherapy induced regression of H and NSCC with delayed recurrence and improved mean survival time.
Collapse
Affiliation(s)
- J Hadden
- Immuno-Rx, Inc., New York, NY, USA.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Dueñas-Gonzalez A, Verastegui E, Lopez-Graniel C, Gonzalez A, Mota A, Barrera-Franco JL, Meneses A, Chanona J, de la Garza J, Chavez-Blanco A, Hadden JW. A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma. Int Immunopharmacol 2002; 2:1007-16. [PMID: 12188025 DOI: 10.1016/s1567-5769(02)00048-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Clinical and experimental data demonstrate that local cytokines are able to induce tumor regression and in some cases antitumor systemic immune response. IRX-2 is a cell-free mixture of cytokines obtained from unrelated donor lymphocytes with demonstrated ability to induce immune mediated regression of squamous cell carcinomas of head and neck. The objective of this study was to evaluate the antitumor activity and toxicity of IRX-2 in untreated early stage cervical cancer patients. Ten consecutive patients clinically staged IB1, IB2 and IIA were treated with a neoadjuvant immunotherapy regimen that consisted in a single IV dose of cyclophosphamide at 300 mg/m2 on day 1, oral indomethacin or ibuprofen and zinc sulfate were administered from days I to 21 and 10 regional perilymphatic injections of IRX-2 on days 3 to 14. All patients were scheduled for radical hysterectomy on day 21. The clinical and pathological responses, toxicity and survival were evaluated. Clinical response was seen in 50% of patients (three partial responses, two minor responses). Seven patients underwent surgery and pathological tumor reduction associated with tumor fragmentation was found in five cases. Histological studies demonstrated a rather heterogeneous cell type infiltrating pattern in the tumor which included lymphocytes, plasma cells, neutrophils, macrophages and eosinophils. Immunohistochemical analysis of the surgical specimens demonstrated an increase of tumor infiltrating CD8+ cells. The treatment was well tolerated except for mild pain and minor bleeding during injections and gastric intolerance to indomethacin. At 31 months of maximum follow-up (median 29), eight patients are disease-free. Our results suggest that the immunotherapy approach used induces tumor responses in cervical cancer patients. Further studies are needed to confirm these results as well as to elucidate the mechanisms underlying these effects.
Collapse
Affiliation(s)
- A Dueñas-Gonzalez
- Instituto Nacional de Cancerologia, Subdirección de Investigacion Basica, Tlalpan, Mexico.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Mice lacking the 5-HT(6) receptor presented neither gross anatomical or behavioral abnormalities nor obvious changes in microscopic brain morphology, and their performance in rotarod, open field and novel object testing paradigms revealed no differences compared with wild-type animals. Nevertheless, an association between the 5-HT(6) receptor polymorphism C267T and Alzheimer's disease has been reported. Interestingly, the 5-HT(6) antisense oligonucleotide decreased 5-HT(6) gene expression and enhanced spatial learning acquisition in the water maze. Similarly, injection of the 5-HT(6) receptor antagonist Ro-04-6790 improved learning consolidation in an autoshaping task, while mCPP, scopolamine and dizocilpine decreased performance. The effect induced by scopolamine or dizocilpine, but not that induced by mCPP, was completely or partially reversed by Ro-04-6790. Ro-04-6790 did not modify the 8-OH-DPAT facilitatory effects on learning consolidation. Since Ro-04-6790 facilitatory effect was unaffected by 5-HT(1A), 5-HT(2A/2B/2C), 5-HT(3), 5-HT(4) or 5-HT(7) receptor blockade, the facilitatory effect induced by Ro-04-6790 involved specifically 5-HT6 receptors. Similarly, the 5-HT(6) receptor antagonist SB-271046 improved retention in the water maze and produced a significant performance improvement in aged rats in an operant-delayed alternation task. A series of Ro-04-6790 analogues that penetrate the brain and specifically bind to 5-HT(6) receptors reversed scopolamine-induced retention deficit in a passive avoidance learning test. Collectively, these data provide further support to the notion that 5-HT systems, via 5-HT(6) receptors, also play a significant role in memory formation under normal and dysfunctional memory conditions.
Collapse
Affiliation(s)
- A Meneses
- Dept. of Pharmacobiology, CINVESTAV-IPN, Mexico City, Mexico
| |
Collapse
|
35
|
Abstract
The present study further explored the mechanisms involved in the facilitatory effect induced by (+/-)-8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) on learning consolidation. For this purpose, we analyzed in parallel the effects of LY215840 and ritanserin, two 5-HT(2) receptor antagonists with high affinity for the 5-HT(7) receptor, and WAY100635, a selective 5-HT(1A) receptor antagonist, on the facilitatory effect induced by 8-OH-DPAT on learning consolidation. We also determined whether LY215840 and/or ritanserin could be beneficial in restoring a deficient learning condition. Using the model of autoshaping task, post-training injection of LY215840 or WAY100635 had no effect on learning consolidation. However, both drugs abolished the enhancing effect of 8-OH-DPAT, with LY215840 being slightly more effective than WAY100635 in this respect. Ritanserin produced an increase in performance by itself and also abolished the effect of 8-OH-DPAT. Remarkably, selective blockade of 5-HT(2A) and 5-HT(2B/2C) receptors with MDL100907 and SB200646, respectively, failed to alter the 8-OH-DPAT effect. LY215840 and ritanserin, at the doses that inhibited the 8-OH-DPAT-induced response, reversed the learning deficits induced by scopolamine and dizocilpine. The present results suggest that the enhancing effect produced by 8-OH-DPAT on learning consolidation involves activation of 5-HT(1A) receptors and an additional mechanism, probably related to the 5-HT(7) receptor. Blockade of 5-HT(2) receptors, and perhaps of 5-HT(7) receptors as well, may provide some benefit in reversing learning deficits associated with decreased cholinergic and/or glutamatergic neurotransmission.
Collapse
Affiliation(s)
- A Meneses
- Departamento de Farmacobiología, CINVESTAV-IPN, AP 22026, 14000 Mexico City, Mexico.
| | | |
Collapse
|
36
|
Abstract
This is a report of an unusual anaplastic thyroid carcinoma case with capsule and long disease-free survival. This 74-year-old male, with an asymptomatic nodule in the mid-line neck for 5 years, was treated with total thyroidectomy. Light microscopy and immunohistochemistry showed an anaplastic carcinoma of the thyroid isthmus. There were no signs of carcinoma elsewhere either at the time of surgery or 35 months later, when the patient was last seen.
Collapse
Affiliation(s)
- L Guimarães
- Discipline of Special Pathology, Triangulo Mineiro Medical School and Dr. Hélio Angotti Hospital, Uberaba, Brazil
| | | | | | | |
Collapse
|
37
|
Abstract
Diverse evidence indicates that, the 5-HT system might play a role in learning and memory, since it occurs in brain areas mediating such processes and 5-HT drugs modulate them. Hence in this work, in order to explore further 5-HT involvement on learning and memory 5-HT1B receptors' role is investigated. Evidence indicates that SB-224289 (a 5-HT1B receptor inverse agonist) post-training injection facilitated learning consolidation in an associative autoshaping learning task, this effect was partially reversed by GR 127935 (a 5-HT1B/1D receptor antagonist), but unaffected by MDL 100907 (a 5-HT2A receptor antagonist) or ketanserin (a 5-HT1D/2A/7 receptor antagonist) at low doses. Moreover, SB-224289 antagonized the learning deficit produced by TFMPP (a 5-HT1A/1B/1D/2A/2C receptor agonist), GR 46611 (a 5-HT1A/1B/1D receptor agonist), mCPP (a 5-HT2A/2C/3/7 receptor agonist/antagonist) or GR 127935 (at low dose). SB-224289 did not alter the 8-OH-DPAT (a 5-HT1A/7 receptor agonist) learning facilitatory effect. SB-224289 eliminated the deficit learning produced by the anticholinergic muscarinic scopolamine or the glutamatergic antagonist dizocilpine. Administration of both, GR 127935 (5mg/kg) plus ketanserin (0.01 mg/kg) did not modify learning consolidation; nevertheless, when ketanserin dose was increased (0.1-1.0mg/kg) and SB-224289 dose was maintained constant, a learning facilitation effect was observed. Notably, SB-224289 at 1.0mg/kg potentiated a subeffective dose of the 5-HT1B/1D receptor agonist/antagonist mixed GR 127935, which facilitated learning consolidation and this effect was abolished by ketanserin at a higher dose. Collectively, the data confirm and extend the earlier findings with GR 127935 and the effects of non-selective 5-HT(1B) receptor agonists. Clearly 5-HT1B agonists induced a learning deficit which can be reversed with SB-224289. Perhaps more importantly, SB-224289 enhances learning consolidation when given alone and can reverse the deficits induced by both cholinergic and glutamatergic antagonist. Hence, 5-HT1B receptor inverse agonists or antagonists could represent drugs for the treatment of learning and memory dysfunctions.
Collapse
Affiliation(s)
- A Meneses
- Depto. de Farmacobiología, CINVESTAV-IPN., AP 22026 14000, Mexico City,
| |
Collapse
|
38
|
Abstract
The 5-HT(6) receptor antagonist Ro-04-6790 or 8-OH-DPAT injection improved learning consolidation on an autoshaping task, while mCPP, scopolamine and dizocilpine decreased the performance. The effect induced by scopolamine, but not that induced by mCPP, was reversed completely by Ro-04-6790, while dizocilpine effect was antagonized partially. Nevertheless, ritanserin or WAY 100635, but not Ro 04-6790, antagonized the 8-OH-DPAT facilitatory effects on learning consolidation. As WAY 100635 did not modify the Ro 04-6790 facilitatory effect, hence 5-HT(1A), and/or 5-HT(7), but not 5-HT(6), receptors might mediate the 8-OH-DPAT facilitatory effect on learning consolidation. Since, the Ro 04-6790 facilitatory effect was unaffected by 5-HT(1A), 5-HT(2A)/(2B)/(2C), 5-HT(3) or 5-HT(4) receptor blockade, thereby, the facilitatory effect induced by Ro 04-6790 involved specifically 5-HT(6) receptors. Indeed, the present data provide further support to the notion that, 5-HT(6) receptors play a significant part in the learning consolidation under normal and dysfunctional memory conditions.
Collapse
Affiliation(s)
- A Meneses
- Depto. de Farmacología y Toxicologia, Terapeutica Experimental, CINVESTAV-IPN, AP 22026, 14000, DF, Mexico City, Mexico.
| |
Collapse
|
39
|
Hong E, Orozco G, Meneses A, Fillion G. Effect of 5-HT-moduline, an endogenous peptide, in associative learning. Proc West Pharmacol Soc 2000; 42:37-8. [PMID: 10697683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Affiliation(s)
- E Hong
- Dept. Pharmacology & Toxicology, CINVESTAV-IPN, México, D.F., México
| | | | | | | |
Collapse
|
40
|
Calderón-Garcidueñas L, Delgado R, Calderón-Garcidueñas A, Meneses A, Ruiz LM, De La Garza J, Acuna H, Villarreal-Calderón A, Raab-Traub N, Devlin R. Malignant neoplasms of the nasal cavity and paranasal sinuses: a series of 256 patients in Mexico City and Monterrey. Is air pollution the missing link? Otolaryngol Head Neck Surg 2000; 122:499-508. [PMID: 10740168 DOI: 10.1067/mhn.2000.103080] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Air pollution is a serious health problem in major cities in Mexico. The concentrations of monitored criteria pollutants have been above the US National Ambient Air Quality Standards for the last decade. To determine whether the number of primary malignant nasal and paranasal neoplasms has increased, we surveyed 256 such cases admitted to a major adult oncology hospital located in metropolitan Mexico City (MMC) for the period from 1976-1997 and to a tertiary hospital in Monterrey, an industrial city, for the period from 1993-1998. The clinical histories and histopathologic material were reviewed, and a brief clinical summary was written for each case. In the MMC hospital the number of newly diagnosed nasal and paranasal neoplasms per year for the period from 1976-1986 averaged 5.1, whereas for the next 11 years it increased to 12.5. The maximal increase was observed in 1995-1997, with an average of 20.3 new cases per year (P = 0.0006). The predominant neoplasms in these series were non-Hodgkin's lymphoma, squamous cell carcinoma, melanoma, adenocarcinoma, Schneiderian carcinoma, and nasopharyngeal carcinoma. In the Monterrey hospital a 2-fold increase in the numbers of newly diagnosed nasal and paranasal neoplasms was recorded between 1993 and 1998. The predominant MMC neoplasm in this series, namely nasal T-cell/natural killer cell non-Hodgkin's lymphoma, is potentially Epstein-Barr virus related. Nasal and paranasal malignant neoplasms are generally rare. Environmental causative factors include exposure in industries such as nickel refining, leather, and wood furniture manufacturing. Although epidemiologic studies have not addressed the relationship between outdoor air pollution and sinonasal malignant neoplasms, there is strong evidence for the nasal and paranasal carcinogenic effect of occupational aerosol complex chemical mixtures. General practitioners and ear, nose, and throat physicians working in highly polluted cities should be aware of the clinical presentations of these patients. Identification of this apparent increase in sinonasal malignant neoplasms in two urban Mexican polluted cities warrants further mechanistic and epidemiologic studies.
Collapse
Affiliation(s)
- L Calderón-Garcidueñas
- Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Meneses A, Mohar A, de la Garza-Salazar J, Ramírez-Ugalde T. Prognostic factors on 45 cases of phyllodes tumors. J Exp Clin Cancer Res 2000; 19:69-73. [PMID: 10840939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The authors, in order to obtain a diagnostic index for phyllodes tumors and identified histological parameters that will predict the clinical course of this neoplasm, developed a histological degree of aggressiveness based on specific histological parameters, including: stromal:gland ratio, tumor margins, mitotic index and degree of stromal pleomorphism. Three categories were established: benign, intermediate and malignant. The probability of recurrence was estimated by the relative risk and by a multivariate Cox analysis. A strong and significant association was observed between this histological index and recurrence. The relative risk was 6.0 for intermediate lesions and 11.4 for malignant lesions when compared with the benign category. The microscopic examination of all axillary lymph nodes was negative for metastatic disease. In the multivariate analysis, the stroma:gland ratio was the strongest predictor for recurrence. These results indicate that by assigning a numerical value to certain histopathologic variables a better correlation with the clinical outcome of the patient can be obtained.
Collapse
Affiliation(s)
- A Meneses
- Division of Pathology, Instituto Nacional de Cancerología, UNAM, Mexico City, Mexico
| | | | | | | |
Collapse
|
42
|
Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg 2000; 126:345-51. [PMID: 10722007 DOI: 10.1001/archotol.126.3.345] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
OBJECTIVES To test the efficacy of a natural cytokine mixture (IRX-2), cyclophosphamide, indomethacin, and zinc to induce immune regression of squamous cell carcinoma (SCC) of the head and neck (H&N) prior to conventional therapy and to characterize the responses. PATIENTS AND DESIGN A phase 2 trial was performed in 15 adults with recently diagnosed, biopsy-confirmed H&N SCC (3 with stage II disease, 6 with stage III disease, and 6 with stage IV disease). The patients were treated with 20 days of perilymphatic injections of IRX-2 (administered subcutaneously at the base of the skull) in combination with contrasuppression consisting of a low-dose infusion of cyclophosphamide (300 mg/m2), and daily oral indomethacin and zinc (StressTabs) in a 21-day cycle before surgery and/or radiotherapy. Tumor dimensions, toxic effects, and disease-free survival were monitored. The tumor sections were histologically examined after surgery, and tumor reduction, fragmentation, and lymphoid infiltration were assessed. RESULTS All 15 patients responded clinically to the 21-day IRX-2 protocol: 1 with a complete response, 7 with a partial response, and 7 with a minor response. All 15 patients responded pathologically with tumor reduction (mean, 42%) and fragmentation (mean, 50%) in the histological section and increased lymphoid infiltration. The adverse effects of the IRX-2 protocol were negligible except for an allergic skin rash (n = 1) and parotiditis (n = 1). Indomethacin caused gastritis in 1 patient. Reduction of pain and ulceration and bleeding were observed in 8 and 4 patients, respectively. Four of 5 patients with lymphopenia showed increased CD3, CD4, and CD8 cell counts. After surgery (n = 13) and/or radiotherapy (n = 10) and with a mean follow-up of 17 months, 3 patients have had recurrences, 1 patient has died of disease, 1 patient has been re-treated with immunotherapy and has no evidence of disease, and 1 patient is alive with disease. Two patients died of other causes with no evidence of disease. CONCLUSIONS The IRX-2 immunotherapy induced lymphocyte mobilization and infiltration in H&N SCC associated with clinical and histological tumor responses indicative of immune regression in all 15 patients. Minimal toxic effects were observed, and overall survival may have been improved. A phase 3 trial seems warranted.
Collapse
Affiliation(s)
- J L Barrera
- Department of Surgery, National Institute of Cancerology, Mexico City, Mexico
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
The study of 5-hydroxytryptamine (5-HT) system has benefited from the identification, classification and cloning of multiple 5-HT receptors (5-HT1 to 5-HT7). Growing evidence suggests that 5-HT is important in learning and memory and all its receptors might be implicated in this. Actually, 5-HT pathways, 5-HT reuptake site/transporter complex and 5-HT receptors show regional distribution in brain areas implicated in learning and memory. Likewise, the stimulation or blockade of presynaptic 5-HT1A, 5-HT1B, 5-HT(2A/2C) and 5-HT3 receptors, postsynaptic 5-HT(2B/2C) and 5-HT4 receptors and 5-HT uptake/transporter sites modulate these processes. Available evidence strongly suggests that the 5-HT system may be important in normal function, the treatment and/or pathogenesis of cognitive disorders. Further investigation will help to specify the 5-HT system nature involvement in cognitive processes, pharmacotherapies, their mechanisms and action sites and to determine under which conditions they could operate. In this regard, it is probable that selective drugs with agonists, neutral antagonist, agonists or inverse agonist properties for 5-HT1A, 5-HT(1B/1D), 5-HT(2A/2B/2C), 5-HT4 and 5-HT7 receptors could constitute a new therapeutic opportunity for learning and memory alterations.
Collapse
Affiliation(s)
- A Meneses
- Departamento de Farmacología y Toxicología, CINVESTAV-IPN, México D.F., Mexico.
| |
Collapse
|
44
|
Meneses A. Are 5-HT(1B/1D) and 5-HT(2A/2B/2C) receptors involved in learning and memory processes? IDrugs 1999; 2:796-801. [PMID: 16127655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Pharmacological data provide clear evidence that 5-HT(1B/1D) and 5-HT(2A/2B/2C )receptors are involved in the consolidation of learning.
Collapse
Affiliation(s)
- A Meneses
- Department of Pharmacology & Toxicology, CINVESTAV, AP 22026 Mexico City 14000, Mexico.
| |
Collapse
|
45
|
Abstract
Attempts were made to further analyze the role of 5-HT1A receptors in consolidation of learning by evaluating the role of these receptors in cognitively normal and impaired animals. The effects of post-training administration of 8-OH-DPAT and 5-HT1A receptor antagonists, WAY 100135, WAY 100635, and S-UH-301, plus the cholinergic and glutamatergic antagonists, scopolamine and dizolcipine, respectively, were determined using an autoshaping learning task. The results showed that 8-OH-DPAT increased the number of conditioned responses, whereas WAY100135, WAY100635, and S-UH-301, and the 5-HT depleter, p-chloroamphetamine (PCA), had no effect. PCA did not change the silent properties of the 5-HT1A receptor antagonists. PCA, WAY100635, and S-UH-301, but not GR127935 (a 5-HT1B/1D-receptor antagonist) or MDL100907 (a 5-HT2A receptor antagonist), reversed the effect to 8-OH-DPAT. Ketanserin (a 5-HT2A/2C receptor antagonist) and ondansetron (a 5-HT3 receptor antagonist), at a dose that increased the conditioned responses by itself, reversed the effect of 8-OH-DPAT. Moreover, 8-OH-DPAT or S-UH-301 reversed the learning deficit induced by scopolamine and dizocilpine whereas WAY100635 reversed the effect of scopolamine only. These data confirm a role for presynaptic 5-HT1A receptors during the consolidation of learning and support the hypothesis that serotonergic, cholinergic, and glutamatergic systems interact in cognitively impaired animals.
Collapse
Affiliation(s)
- A Meneses
- Terapéutica Experimental, Departamento de Farmacología y Toxicología, México, D.F., 14000, México
| | | |
Collapse
|
46
|
Abstract
Multiple 5-hydroxytryptamine (5-HT) receptors have been identified (5-HT1A/1B/1D/1E/1F, 5-HT2A/2B/2C, 5-HT3A/3B, 5-HT4A/4B, 5-HT5A/5B, 5-HT6 and 5-HT7A/7B/7C/7D) and extensive evidence suggests that 5-HT receptors have a role in learning and memory. Indeed, available evidence strongly supports physiological, pathophysiological and therapeutic roles of 5-HT systems in cognitive processes, although the evidence seems incomplete. Indeed, there has been a clear tendency to use pre-learning administration most frequently, whereas post-learning and pre-retention administration protocols have been utilized in only a few studies, and probably this trend has led to missed relevant information. For instance, when pre- vs post-training administration of 5-HT1A agonist, 5-HT2 antagonists and 5-HT4 agonists have been compared contrasting findings were reported in aversive and appetitive learning tasks. Emerging evidence also indicates that 5-HT1A and 5-HT4 receptor agonists, as well as, 5-HT1A antagonists, 5-HT2 antagonists, 5-HT3 antagonists and 5-HT uptake inhibitors may have therapeutic utility in the treatment of Alzheimer's disease and amnesia. Inasmuch as the activation or blockade of diverse 5-HT receptors is able to modulate cognitive processes, and 5-HT uptake inhibition could have therapeutic applications in the treatment of cognitive disorders, it seems evident that the role of 5-HT in learning and memory is more complex than a simple imbalance. Consequently, the notion that activation of the 5-HT systems impairs performance, whereas reduced serotonergic function may facilitate learning, must be reconsidered.
Collapse
Affiliation(s)
- A Meneses
- Terapéutica Experimental, Departamento de Farmacología y Toxicología CINVESTAV-IPN, México City, México
| |
Collapse
|
47
|
Affiliation(s)
- A Meneses
- Department of Pharmacology and Toxicology, CINVESTAV-IPN, México, D.F., México.
| | | | | |
Collapse
|
48
|
Affiliation(s)
- B Aldape
- Facultad de Odontologia, Universidad Nacional Autonoma de Mexico (UNAM)
| | | | | | | | | | | |
Collapse
|
49
|
Abstract
It is now well established that the clinical and histopathological characteristics of non-Hodgkin's lymphomas may vary significantly throughout the world. However, only a few reports have been published in Latin American countries. In this work, the clinical and pathologic findings of 264 patients with non-Hodgkin's lymphomas in Mexico City were analyzed. Diffuse large (14%) and diffuse mixed cell types (20%) predominated among nodal lymphomas. Within the group of patients with high grade malignancies, immunoblastic sarcomas were the most common (40/48). It is important to mention that follicular lymphomas were sporadic (4.5%). Among extranodal lymphomas the most commonly involved site was the gastrointestinal tract (11.3%), followed by the midline (6%). Molecular analysis of 65 cases with immunoglobulin and T-cell receptor gene probes showed that most lymphomas were of B-cell lineage (66%). The remaining group was composed of T-cell (25%) and bigenotypic malignancies (9%). All attempts to establish a correlation between the clinical stage and histopathological types with the genetic findings were not successful. However, pre-B and bigenotypic lymphomas were observed mainly in patients over 60 years of age. This study highlights some relevant characteristics of non-Hodgkin's lymphomas in Mexico.
Collapse
Affiliation(s)
- V Ortega
- División de Investigación Básica, Instituto Nacional de Cancerología, México D.F., Mexico
| | | | | | | | | | | |
Collapse
|
50
|
Keesee SK, Marchese J, Meneses A, Potz D, Garcia-Cuellar C, Szaro RP, Solorza G, Osornio-Vargas A, Mohar A, de la Garza JG, Wu YJ. Human cervical cancer-associated nuclear matrix proteins. Exp Cell Res 1998; 244:14-25. [PMID: 9770344 DOI: 10.1006/excr.1998.4202] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The nuclear matrix is the nonchromatin protein structural component of the nucleus that governs nuclear shape and also exerts regulatory control over higher order gene organization. Recent studies have documented the presence of tumor-associated nuclear matrix proteins in several human cancers. We used high-resolution two-dimensional gel electrophoresis to compare nuclear matrix protein patterns in cervical carcinomas with those from normal cervical tissue. Tumors obtained from 20 patients undergoing hysterectomy for clinically localized cervical cancer were compared with normal cervical tissue. We have identified five polypeptides (CvC-1: Mr = 69,408 Da, pI = 5. 78; CvC-2: Mr = 53,752 Da, pI = 5.54; CvC-3: Mr = 47,887 Da, pI = 5. 60; CvC-4: Mr = 46,006 Da, pI = 5.07; and CvC-5: Mr = 44,864 Da, pI = 6.61) in the nuclear matrix from cervical carcinomas that were present in 20 of 20 cervical tumors but 0 of 10 normal tissues. These data extend similar findings of cancer-associated nuclear matrix proteins in other human cancers and suggest that nuclear matrix proteins may represent a new class of cancer markers that could aid the diagnosis or management of some types of cancer.
Collapse
Affiliation(s)
- S K Keesee
- Matritech, Inc., 330 Nevada Street, Newton, Massachusetts, 02160, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|